Literature DB >> 11460576

Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance.

H Mehnert1.   

Abstract

Metformin should be regarded as a first-choice therapy of type 2 diabetes, showing an especially good efficacy in obese patients with hyperinsulinaemia. Reduction of blood glucose without hyperinsulinaemia and without hypoglycaemia, favourable influence on the lipid profile and inhibition of coagulation factors lead to an antidiabetic and antiatherogenic effect. Not only are these characteristics relevant to judging the value of the drug, but also the strict observation of contraindications is needed to avoid the dangerous complication of lactic acidosis.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11460576     DOI： 10.1055/s-2001-18587

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN： 0947-7349            Impact factor:   2.949


  12 in total

1.  Metformin inhibits IL-1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis.

Authors:  Gaku Tsuji; Akiko Hashimoto-Hachiya; Vu Hai Yen; Masaki Takemura; Ayako Yumine; Kazuhisa Furue; Masutaka Furue; Takeshi Nakahara
Journal:  Cell Death Discov       Date:  2020-03-04

Review 2.  Pharmacotherapy in the Management of Pediatric Obesity.

Authors:  Aaron S Kelly; Claudia K Fox
Journal:  Curr Diab Rep       Date:  2017-08       Impact factor: 4.810

3.  Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.

Authors:  Hind Beydoun; Vijaya Kancherla; Laurel Stadtmauer; May Beydoun
Journal:  Gynecol Endocrinol       Date:  2013-01-17       Impact factor: 2.260

Review 4.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Pharmacotherapy for childhood obesity: present and future prospects.

Authors:  R Sherafat-Kazemzadeh; S Z Yanovski; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2012-08-28       Impact factor: 5.095

Review 6.  An evolving scientific basis for the prevention and treatment of pediatric obesity.

Authors:  P T Katzmarzyk; S Barlow; C Bouchard; P M Catalano; D S Hsia; T H Inge; C Lovelady; H Raynor; L M Redman; A E Staiano; D Spruijt-Metz; M E Symonds; M Vickers; D Wilfley; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2014-03-25       Impact factor: 5.095

7.  Anti-diabetic effects of CTB-APSL fusion protein in type 2 diabetic mice.

Authors:  Yunlong Liu; Zhangzhao Gao; Qingtuo Guo; Tao Wang; Conger Lu; Ying Chen; Qing Sheng; Jian Chen; Zuoming Nie; Yaozhou Zhang; Wutong Wu; Zhengbing Lv; Jianhong Shu
Journal:  Mar Drugs       Date:  2014-03-13       Impact factor: 5.118

8.  Effect of dietary nonstructural carbohydrate content on activation of 5'-adenosine monophosphate-activated protein kinase in liver, skeletal muscle, and digital laminae of lean and obese ponies.

Authors:  T A Burns; M R Watts; P S Weber; L J McCutcheon; R J Geor; J K Belknap
Journal:  J Vet Intern Med       Date:  2014-04-20       Impact factor: 3.333

9.  Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).

Authors:  Surjit Singh; Anil Bhansali
Journal:  BMC Dermatol       Date:  2016-08-17

Review 10.  AMPK activation: a therapeutic target for type 2 diabetes?

Authors:  Kimberly A Coughlan; Rudy J Valentine; Neil B Ruderman; Asish K Saha
Journal:  Diabetes Metab Syndr Obes       Date:  2014-06-24       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.